Okanagan-born nanoscientist thinking small in a big way – BCLocalNews

Building a structure out of toothpicks and glue takes creativity, patience and careful planning. But imagine trying to build a similar structure which height is the thickness of a piece of paper. The beams and supports, a 50th the thickness. Sounds impossible, right?

Although he cant see them with his naked eye, nanoscientist and Penticton native Nigel Clarke has been building these microscopic structure, as well as other creations, for years. For nanoscientists, thinking small in a big way is key.

Based out of Mountain View, California, Clarke works to explore new product ideas with Samsungs Thing Tank Team. His day-to-day is spent brainstorming and building new creations; from new TV displays to virtual reality, and even robot arms that cook in your kitchen.

Born and raised in Penticton, the now 27-year-old Senior Research Engineer is working to develop game-changing technology which could affect many things.

[Story continues below]

[Nanoscientist and research engineer, Nigel Clarke. Supplied]

I always liked inventing things, so I wanted to be on the bleeding edge of something, said Clarke. So when I first about nanotechnology, I was immediately attracted to it. Because it seemed like such a new field, there were so many opportunities to create new things.

After graduating from Penticton Secondary School in 2010 and the University of Waterloo for Nanotechnology Engineering in 2015, Clarke went on to receive his masters in Mechanical Engineering and Design Methodology from Stanford University in 2018. His masters was based on the most efficient way of testing and learning from products in order to figure out what should be produced.

Throughout his education he explored nanofabrication and the creation of objects so small, their structure cannot be fully appreciated with light-based microscopes.

By designing these microscopic structures, scientists can observe how certain materials behave. This allows them to create structures with unique properties, not normally seen in larger materials.

Clarke has previously worked with a group, led by California Institute of Technology professor Julia Greer, to develop this technology and turn it into something practical.

In addition to these microscopic structures, Clarke has also researched how light behaves differently at the nanoscale, which helped in the development health sensors. He also worked on the development of thin flexible electronics, used in contact lenses.

Imagine shining light through a microscope; at a certain point the ray of light is so concentrated that it has the ability to burn. At the very centre of this hourglass shape, the light is the brightest.

To start the creation of these microscopic structures, Clarke covers a surface with a light-sensitive material, Photoresist, which reacts when it comes into contact with light. When exposed to light, the Photoresist then changes from appearing like a liquid, to appearing like a solid. In other words areas that are exposed to the bright light crosslink and become a hard material, eventually forming a structure.

By moving lasers around in 3D space, they can draw microscopic structures one line at a time out of thin air.

The main thing this group was trying to do was look at these unique properties that you only get at the nano scale, pretty much a strength improvement in this normally brittle material and say; are there ways that we can bring that type of property to larger materials that we use every day, said Clarke.

In future, this could result in the creation of extremely strong structures which are also very lightweight. One use already implemented is the creation of artificial bone.

To see Clarkes photos up close, visit the St. Germain caf downtown Penticton where they are currently on display. He credited his mother for allowing him to view his photographs as art, and showcase them to the world.

READ MORE: Morning Start: Did you know there is a liquid you can breathe like air?

@PentictonNews editor@pentictonwesternnews.comLike us on Facebook and follow us on Twitter.

Lake Country Calendar

See original here:

Okanagan-born nanoscientist thinking small in a big way - BCLocalNews

What can save the world? – It’s All About . . . – Castanet.net

Mark Jennings-Bates -Mar 13, 2020 / 6:00 am | Story:279331

Photo: hidenanalytical.com

Can nanotechnology save the world?

I believe it can and goodness knows we need some solution for what is going on whether it is:

We likely only have ourselves to blame for the challenges we are experiencing.

While the world struggles to contain the ripples from theCovid19 outbreak, some people are hard at work in labs and R&D centres around trying to find new world solutions.

It turns out those solutions come in a very tiny form and the potential for nano particles is, lets say, explored, but not implemented.

To give you an idea how small a nano particle typically is, a piece of writing or copy paper is approximately 0.05mm thick.

By comparison, 1mm is equivalent to 1,000,000 nano metres and a nano particle ranges between 1nm and 100nm. I hope you see the point, but you wont ever see a nano particle with the naked eye.

But why is something so small able to change the future of the world?

Turns out there is a lot of answers from a short question so over the next few weeks, I want to explore a burgeoning industry and talk about why nanotechnology can in fact save the world.

When you take a deep dive in to the subject, you will see that nano particles have been around for a long time, and secondly that development is advancing at a rapid rate with our knowledge of what they can be used for increasing exponentially.

Literally, we can find examples of nano particles being used very successfully in areas like road construction through to anti bacterial and anti viral applications in the medical industry.

How? Well lets start getting in to it a little more than next week.

COMMENTS WELCOME

Comments are pre-moderated to ensure they meet our guidelines. Approval times will vary. Keep it civil, and stay on topic. If you see an inappropriate comment, please use the flag feature. Comments are the opinions of the comment writer, not of Castanet. Comments remain open for one day after a story is published and are closed on weekends. Visit Castanets Forums to start or join a discussion about this story.

View post:

What can save the world? - It's All About . . . - Castanet.net

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration…

PARIS--(BUSINESS WIRE)--Regulatory News:

Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy, announced the selection of its Nanoprimer technology by the National Cancer Institutes (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization, based on its potential to significantly impact treatments in multiple disease indications, including cancer.

The broad utility of the Nanoprimer technology is due to its unique nanomedicine approach to improve therapeutic action without modifying the therapeutic in any way. Rather, the Nanoprimer is administered intravenously just prior to a therapeutic, specifically and transiently occupying the liver pathways responsible for clearance. This temporarily increases the therapeutics bioavailability and subsequent accumulation in target tissue. This mechanism, targeting the universal upstream pathways involved in intravenous drug clearance, means the Nanoprimer can be used in combination with multiple classes of nanomedicines including nucleic acid and small molecule therapeutics or gene editing technologies.

Through this collaboration, the NCL, a leader in the characterization and development of Nanomedicines, will perform in-depth pre-clinical characterizations. These studies will support the Nanoprimers development, driving advancement toward filing an Investigational New Drug (IND) with the Food and Drug Administration (FDA) and future clinical development. This work will also support ongoing and future collaborations combining the Nanoprimer with therapeutics across diverse clinical indications.

Curadigm is a 2019 Nanobiotix spin-off, that aims to reshape and elevate the efficacy of intravenously administered therapeutics. The Nanoprimer technology is based on engineered, biocompatible nanoparticles that are administered just prior to the therapeutic and acts rapidly to temporarily occupy the Kupffer and liver sinusoidal endothelial (LSEC) cells. This precision-based approach leads to enhanced systemic bioavailability for increased therapeutic action.

The NCL was established to study the use of nanoparticles and nanomedicines to advance cancer research and to accelerate the development of promising and safe nanotechnology-based cancer therapeutics. The program provides pre-clinical testing and services on a competitive acceptance basis to companies, such as Curadigm, and is working in concert with other US agencies such as the FDA to accelerate the use of nanomedicines from early-stage development to clinical applications.

The selection of our nanoprimer by the NCL is a major step for Curadigm, said Matthieu Germain, CEO of Curadigm. The standardized cascade assay developed by the NCL is a great opportunity to accelerate the development of the Nanoprimer by providing additional data about its physico-chemical properties, safety and mechanism of action that will facilitate regulatory review. The results generated through this collaboration will also be instrumental in supporting our discussions with partners to develop their therapeutics with the Nanoprimer.

About Curadigm

Curadigm, a Nanobiotix Corp spin-off, is an early-stage nanotechnology company dedicated to improving outcomes for patients by shifting the therapeutic delivery paradigm. Curadigms Nanoprimer technology increases drug bioavailability while decreasing unintended off-target effects, specifically liver & spleen toxicities. The platform can be used with most intravenous (IV) therapeutics across multiple drug classes. Curadigm is dedicated to advancing therapeutic development based on our deep understanding of how drugs interact with the body, to impact both known and novel drugs across multiple clinical indications.

For more information about Curadigm visit http://www.curadigm.com

Read more here:

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration...

Howie Carr: Its time to wake up sleepy Joe Biden – Boston Herald

The next thing the Democrats have to do is get Bolshevik Bernie out of the race before Sunday, which is when the next debate is scheduled.

Sleepy Joe Biden has already been allowed to sit down (the debate is, after all, sponsored by CNN). But the condition that Joe finds himself in now, utterly incoherent, babbling, totally non compos mentis, it wouldnt be enough to wheel him on stage in an iron lung, with an oxygen mask on his face.

They have to cancel that Sunday night debate, dammit! The Deep State has to be saying to themselves, we dont care if we have to buy Breadline Bernie three summer camps on Lake Champlain to get him out of the fight this time, it has to be done!

The former vice president has become a one-man assembly line of gaffes. A few weeks ago, wed get a couple every weekend, and theyd spice up the Monday radio show.

You know, confusing Ohio and Iowa, California and Nevada, rhapsodizing about the beauty of Keene, Vermont.

But as the primaries and caucuses began, the pace intensified.

People of Nevada are watching, he said last month, and Im gonna be out there soon enough. But tonight, though, we just heard from the first two of the 50 states. Its important that Iowa and Nevada have spoken but look, its important we hear from Nevada and South Carolina.

And dont forget Nevada either, Mr. Vice President.

Now we get one or two new gaffes every day. My producer breaks in during the broadcast with the latest howler, like Monday when Biden said, Together I think we can win back the House, before remembering that the glorious victory had occurred 16 months earlier. Short-term memory is always the first thing to go, isnt it?

He also said something else that I spent part of Tuesday morning trying to transcribe. I finally got it, I think, although you cant get sure:

Look, they always say, Biden dismisses China. I dont di-di-dimiss China. But if we invest in ourselves, as they say in a little steel town where I come from, Claymont, Delaware, not a patch on our jeans. (Or was it team?)

But even as I kept trying to decipher the previous days mumbling, Biden was getting into it with a hardhat in Michigan. The guy was asking him about guns, and Slow Joe was babbling about AR-14s and he finally told him, Youre full of (bleep)!

But then, Joe has a problem with guns, I mean beyond the actual Second Amendment.

Who in Gods name needs a hundred rounds in a bullet in a gun you have?

Or, You cannot have 20, 30, 40 clips in a weapon.

On the alt-left networks, they call these gaffes. And the Democrat hacks say, well, he has gaffes but he doesnt lie. Although of course he does remember, just recently, how he was arrested with Nelson Mandela in Soweto oh never mind.

Ive been in debates. I debated Paul Ryan. I debated that woman who could see Russia. Okay?

Okay. In Iowa, he forgot Steve Lynchs name. On Super Tuesday, he introduced his wife as his sister, and vice versa. He called Julian Castro Julio. He thinks Beto ORourke is Latino.

Last weekend he called himself Joe OBiden Bama. He thinks hes running for the Senate, and that a Senate candidate in South Carolina is running for president. He even forgets the name of the man he used to call Barack America. Now he says it was President (long awkward pause) my boss.

President My Boss. Yes, those were the days, when President America picked him to head up the inauguration in January of 2012, actually 2013, no wait a minute, we elected in 2012, 2010 or 13.

Come on, you remember. It was back in the spring, late fall, early sum I mean late spring late winter early fall early anyway, you know what I mean.

We hold these truths to be self-evident. All men and women created by the go you know, the thing

So you go ahead and stack spaghetti sauce at a store and and and a supermarket you control the guy or the woman who runs the runs runs the brings out the carts on on on a forklift

Its comedy gold, but now his handlers are desperately trying to keep his, ahem, remarks short. But that debate on Sunday night, good Lord, even on CNN, which has already tried to disembowel Bernie at least a couple of times.

The only question for the Biden campaign now is, How much, Bernie? How much do you want? And if you want to stay in this fight all the way to Milwaukee Bernie what are you, a lying dog-faced pony soldier?

Read the original here:

Howie Carr: Its time to wake up sleepy Joe Biden - Boston Herald

Netflix is testing cheap new mobile-only plan that costs just 2.40 a month – The Sun

NETFLIX is now trialling a cheap mobile-only plan in four countries around the world.

The bargain subscription works out at around $3 / 2.40, but is only available in select regions for now.

3

The cut-price plan was tested in India and Malaysia last year but is expected to roll out across the globe in the near future.

And it's now been launched in Thailand and the Philippines.

The plan is unusual for Netflix in that you can only watch shows on your mobile.

That means no Netflix on your smart telly or laptop a price you'll have to pay for such a cheap monthly fee.

3

At around 2.40, it's by far the cheapest plan that Netflix offers.

For comparison, UK customers pay a minimum of 5.99 a month for the basic plan though that lets you play shows on your telly, laptop and mobile.

The UK's priciest tier, which gives you HD content on up to four screens at once, now costs 11.99 a month following acontroversial price hikein May.

"We believe that our members may value the flexibility that comes from being able to pay for a few months at once," Netflix said.

Currently, the mobile-only and bundle tiers are only being trialled by Netflix.

So is there any hope for the plan coming to the UK or USA?

One industry insider told The Sun that Netflix's cheap new plan is targeted at emerging markets but that a UK launch couldn't be ruled out.

"The mobile only plan makes sense in markets where people rely on phones to connect with the world," said Paolo Pescatore, of PP Foresight, speaking to The Sun.

"Never rule out new price options to drive further uptake.

"Ultimately people still prefer to browse on their mobile devices and watch on the big screen, if possible.

"More so in high quality formats like 4K, HDR and eventually 8K."

3

A spokesman recently told The Sun there are no plans to launch the tier outside of India at the moment, but did not rule out a broader launch in future.

For now, trials in India and other eastern regions will help the firm figure out if cheaper tiers are a good way to grow its massive user base.

The tech titan predicts that India the world's second most populous nation will be a key battleground in its fight to lure in more users from across the globe.

Use Netflix on a computer or laptop? Try these useful shortcuts

Here are some handy keyboard shortcuts...

VANISHING ACTWhatsApp creates secret self-deleting messages feature to wipe texts forever

A-MARS-ING!Mars has alien LIFE lurking at its icy poles, astronomers believe

FLU GOTTA BE KIDDING MECoronavirus conspiracies including claims it was 'made by CIA'

BUG OFFInstagram bans coronavirus filters including dangerous one that 'diagnoses'

EXIT STRATEGYScientists rank safest spots to flee to in deadly apocalyptic outbreak

NETFLIX AND BRILLSky customers can now get Netflix for free... and here's how

You can read more about Netflix's recent UK price hikehere.

Check out our guide tosecret Netflix codesthat unlock hidden TV series, genres and movie categories.

And use thisNetflix trickto make sure you see fewer rubbish films.

Do you think this plan should come to the UK? Let us know in the comments!

We pay for your stories! Do you have a story for The Sun Online Tech & Science team? Email us at tech@the-sun.co.uk

Read the original here:

Netflix is testing cheap new mobile-only plan that costs just 2.40 a month - The Sun

Life under lockdown: Italy is being consumed by panic – Spectator.co.uk

Ravenna

The whole of Italy is now in quarantine and infected by the kind of panic I imagine an invaded people feels as it waits for the enemy to knock on the door.

I work from home and suppose I must be thankful at least for that. I have just heard the youngest of our six children, Giuseppe, who is four, ask Carla, his mother: Mamma, do you know why its called coronavirus? No, bello, I dont, tell me she replied. Because its the king of tutti i virus! he crowed which caused Carla to smother him with kisses. Bravissimo! Amore mio! Bravissimo! The word corona, in case you didnt know, is Italian for crown. Did he invent that himself I wonder? The whole episode brought a tear to my eye and a surge of impotent anger anger that such a beautiful human gesture, a mother kissing and hugging her small child, could perhaps prove fatal.

Headlines in online Italian newspapers that catch my eye include The virus remains in the air for 30 minutes and travels 4.5 metres, Checks on movement to be done via mobile phone records and Government may order suspension of all loan repayments not that I have a loan, thank God.

The Italian Prime Minister, Giuseppe Conte, announced the closure of Italy in a television address to the nation on Monday night, saying: Our habits must change now and Everyone must remain at home.

We live near Ravenna, in the countryside a mile from the Adriatic coast, and our children rely on us to get in and out of the city a ten-minute drive away. Children seem less prone to catch the virus than any other age group but we have convinced ourselves, I cannot remember quite why, that they can act as symptomless carriers.

Our eldest son, Francesco Winston, is 14 and already as tall as me. He is also stronger than me, though possibly he does not quite realise it yet, and keeps trying to go into Ravenna to see his friends storming off into the dark in search of a bus or something. But when yesterday Carla shouted at him Assassino! (Killer!), that seemed at long last to strike home.

Little Giuseppe does not go to school, but this is the third week the five children who do two boys and three girls have been at home following closure of schools and universities in our region, Emilia--Romagna, thanks to the high infection rate here (the second highest in Italy, though still a long way behind Lombardy). The children are supposed to do homework each day via a schools internet site which at least two of them are unable to access, and no one at school (with which we can communicate only via email and telephone) has been able to solve the problem. Francesco Winston and the eldest, Caterina, 16, are also doing the odd lesson via streaming. It all seems so slapdash but it is better than nothing.

As I write, there have been a total of 10,149 cases of coronavirus in Italy and of these 631 have died. That is a death rate of more than 6 per cent, which is a heck of a lot higher than the 2 per cent death rate that experts talk about. The numbers of those infected in Italy are now growing explosively and terrifyingly. Just a week ago there were a total of 2,000 cases and fewer than 100 deaths. On 21 February less than a month ago there were just 17 cases. It is difficult to see how other European countries such as Britain can avoid a similar catastrophe unless they take pretty drastic action right now, for several weeks, before their case numbers reach Italian levels. The most recent figures I saw (for Monday) showed just 373 cases in Britain but that is the number of cases Italy had on 25 February, just a couple of weeks ago.

Last weekend, Italys government took the extraordinary step of placing in quarantine the whole of Lombardy (whose capital is Milan, the financial engine room of Italy); two days later, the growth in cases forced it to extend the lockdown to the entire country.

According to the governments emergency quarantine decree, which will remain in force until 3 April, no one can leave home without a valid motive. These include work and necessity, such as buying food or taking the dog for a walk. This means no one can leave the province where they live unless they have an urgent reason. Holy Communion in church has been cancelled, as have funeral and wedding ceremonies. Even Serie A football has been suspended. Most sport seems to be cancelled. All public gatherings inside or out are banned. Discotheques, cinemas, museums, galleries, theatres, swimming pools, gyms, you name it all closed.

Factories and offices remain open, as do supermarkets and shops, but the emergency decree insists that everyone must keep a distance of one metre apart in public places. That will be impossible in many restaurants. And impossible anyway to police. Bars must close at 6 p.m. The government a left-wing coalition of alt-left 5 Star and post--communist Democratic Party has agreed with opposition parties that parliament should meet far less frequently and be attended by only half the MPs, to maintain the one-metre rule. Italys European Parliament president Davide Sassoli has self--isolated and will chair debates via computer. Numerous TV shows are cancelled.

Via WhatsApp, audios are circulating from nurses which tell me that the situation in many hospitals even in Emilia--Romagna is apocalyptic and far worse than is being admitted by the authorities, and that in Rimini, just 30 miles away from me, the citys hospital is so overrun that it is turning new coronavirus patients away.

The big problem apart from the fear and the panic is the confusion. This is the governments fault. With regard to the travel ban, for example, one ground for exemption spelled out in the decree is comprovate esigenze lavorative proven work needs. What on earth does that mean? Which work qualifies and how such necessity can be proven are not spelled out. The decree also says that such grounds must be self-certified on a written form but who, then, is going to check whether someone is telling the truth, and how? The punishment for breach of the quarantine measures is up to three months in prison (automatically suspended, since it is less than two years) plus a derisory 206 fine. In the end, it will be up to the Italians themselves either to respect or ignore them.

Roberto Burioni, a leading virologist and medical professor, spelled this out in a dramatic plea to the nation in an interview in Mondays La Stampa, in which he said every Italian must display virtuous behaviour towards himself and towards the community and make big sacrifices because we have before us a dangerous enemy.

An enemy that is totally invisible.

Read more:

Life under lockdown: Italy is being consumed by panic - Spectator.co.uk

The Death Throes of the Failed Sandernista Revolution – Real Context News

The formal war is ending, and tonight is almost certainly the last time Sanders can put up any serious resistance in a delegate-rich state. His Waterloo will be Michigan. The only real question is if Sanders surrenders gracefully like General Lee at Appomattox or pulls a Saddam Hussein and allows his forces to melt away in order to mount a vicious guerrilla campaign once the big formal battles are over.

By Brian E. Frydenborg(LinkedIn,Facebook,Twitter@bfry1981)March 10, 2020 (this was written, if not fully edited, before results came in tonight); see related articles: The Best Guide to Super Tuesday (no, seriously): Bidens Got This (and the Nomination), Democrats Look Disastrous, But Biden May Yet Save Them from Themselves Starting in South Carolina, Sandernista Political Terrorism II: Sanders Derangement Syndrome, the Liberal Tea Party, & How Nevada Riot Pretty Much Sums Up Team Bernie, and The Sandernista Political Revolution Handbook: A Matchup Game of Bernie Sanders Talking Points & Those of His Fans/Supporters

WASHINGTON AND ARLINGTONAs I have noted repeatedly before, the lack of self-awareness among Bernie Sanders and his Sandernista would-be-fellow revolutionaries is among the most irritating of their (many) irritating traits. In particular, at this stage in the quest for the Democratic Partys presidential nomination (or, as many Bernie Sanders supporters would think of it, the quest to hijack, destroy internally, and replace the Democratic Party with a democratic socialist party), one thing that strikes me This has been something has long bothered me, but as Bernieworld becomes increasingly unhinged, they act as if they have a monopoly on disappointment, frustration, anger, and rage within the left. They are indignant about how the media, other candidates, and other supporters talk about and frame them and their candidate, yet rarely pause to consider if, let alone acknowledge that, other candidates and their supporters have similar feelings directed at not just the media but back at Bernieworld (and, yes, the other major candidates, from Sen. Elizabeth Warren to former Mayor Pete Buttigieg, have made clear that Bernie bros are in a category all their own on the left). A group that in part lives off of their rage at what they term The Establishment and at any and all criticism directed their wayno matter how smallcannot seem to even fathom that they themselves may also cause offense, be unfair, should adjust how they speak and act towards others. In fact, the mere suggestion of this seems to send them into even more rage, with their best reaction usually righteous indignation.

As is the case regarding so much with Bernie Sanders, his supporters, and Sandersism, there is their talk and then there is the massive gap between talk and reality.

In 2016, his arguments were largely disproven by thedramatic way in which voters rejected their premises, with 3.7+ million more voterspreferring Clinton, and this was with 14 states (28% of all states) holdingcaucuses, undemocraticand unrepresentative abominations that greatly depress turnout and overrepresentthe enthusiastic and those without certain burdens (like having kids). The net political effect of these caucuses wasto dramatically inflate voting margins in Bernies favor, as Sanders blewClinton out of the water in 12 of those 14 caucus states and only lost relativelynarrowly in the other 2. To ram thispoint home, in 2 of these states that Sanders won (Nebraska and Washingtonstate) among the 12 of the caucuses he won, Clinton even won nonbindingprimaries (or normal votes) that had far greater turnout. Sanders, then, would have almost certainlyhave lose some caucus states he won if they were primaries (which happened in2020 with Minnesota and Maine ditching caucuses) and his margin woulddefinitely have been much lower even in the caucus states he won and incaucuses in general. In other words, the3.7-million-vote margin of victory for Clinton would have been significantlylarger with representative primaries and the gap between Clinton and Sanders wouldactually be larger with voters than the numbers we have from 2016 would suggest.

In 2016, Democratic turnout was dramatically lower (30.6 million) than in 2016 (37.1 million). Basically, Hillary Clintonone of the top faces of the Democratic Party for decadessoundly beat Sanders because Democrats liked her for president much more than Bernie, and the idea that brand new voters were going to join the Democratic Party to shift it dramatically to the left into democratic socialist territory, that Bernie was going to be the inspiration for this high turnout and new voters flies in this face of these considerations.. Especially with young people, that turnout did not happen. Instead, Democrats chose a far more traditional candidate (though revolutionary in her identity as far as her being a woman, the first major-party female nominee for president in American history) rather that an insurgent and a campaign that sought to overthrow the system as a whole. Democrats actually like the Democratic Party, and Clinton garnered close over 3.7 million more votes than Sanders even with the caucus factor diluting Clintons margins. So, while as a woman, Clinton could claim something of an outsider status, too, her politics were pretty institutional and mainstream in many ways and especially compared to Sanders. Clinton was also one of the top faces of the Democratic Party for decades and handily outperformed Bernie with Democrats, so the idea that the American left overall hates the Democratic Party, hates its Establishment figures like, say, Hillary, or Barack Obama, or Speaker Nancy Pelosi, or Whip Jim Clyburn, simply has no factual basis. Bernie campaigned against the Democratic Party itself as well as its leaders, but it turns out Democratic voters like them just fine. So the notion that Bernie Sanders himself is somehow going to drive historic turnoutwhen turnout was way down in 2016 from 2008 when when Sanders was one of two major contenders in a race in which Sanders got beat by some 3.7 million votes even with dramatically lower turnoutis patently absurd and has no logical or empirical basis to support it.

For the sake of argument, though, let us even pretend that the exact same arguments were not made in 2016, plainly for all to hear, and that they were not dramatically disproven in a Democratic nomination contest that underrepresented Clintons support in 28% of all state contests that held caucuses. Lets pretend we are in a brave new world (Sanders and his people like to make the claim that the electorate has dramatically changed in just the past few years) and look at how his political performance in contests so far in 2020 matches his claims; lets see how much his bark matches his bite.

Premise/Assumption: People were tired of the Democratic Party and the way it did things. Instead, they would choose a new, revolutionary campaign, one with which they could smash the Establishment.

Reality: There has so far only been one state where Bernie Sanders did not receive fewer votes than more proud-to-be-actual-Democrats Democrats combined: his home state of Vermont, the only state in 2020 thus far where he has received more than 50% of the vote. Despite the narrative that the alt-left progressive non-Democrat leftists would sell, the simple reality is that Democrats overall were happy with a number of candidates in the 2020 field and with the Party overall; Speaker Nancy Pelosi is popular with a vast majority of Democrats, too. Whats better than polls and approval ratings, thought, is votes, and with Sanders receiving less than 30% of the overall vote so far, voters have overwhelming preferred existing Democrats to those who want to smash the Democratic Party. In most states, Sanders has been in 20s, a few in the teens, and some in 30s as far as vote/caucus delegate percent-share, but in no states prior to today besides his home state of Vermont and Nevada has this threshold passed 37%. The American far-left loves Sanders, but, as I have pointed out before, this is a country where only six states have more liberals than conservatives. No, this is not a man building a broad movement that can succeed on a national level, just a fraction of a faction that can disrupt and destabilize the left but has little talent or ability beyond that.

Premise/assumption: Bernie Sanders is a generational transformational figure who will inspire turnout at historic, unprecedented levels; his claim to having this ability is the central premise to his argument of a.) how he can win the nomination, b.) how he can win the general election, and c.) somehow, without ever actually explaining it, how he will govern and how he will get his agenda passed amidst intense opposition (the oft-heard million of people in the streets phrase).

Reality: Even when Bernie won states in this 2020 cycleother than his own state of Vermontloud and proud members of the actual Democratic Party (Bernie is still an independent) got far more votes combined (yes, even in California), often dramatically more votes when combined. Where turnout is increasing, its increasing, generally, in states going strongly for Biden and dramatically so. So Bernie has failed to do the very thing he claimed he, uniquely, could do, while Biden actually did it, not with phantom progressives but with actual suburban swing voters that are the real key to elections. And youth turnout was typically low; there was no #BernieSurge. In every state contest so far, Sanders has received fewer votes (or state delegate percentages) than he did in 2016, and in most cases, the drop has been dramatic. Even in his home state of Vermont, Sander received an over 35% lower portion of the votes (50.7%) than he did in 2016 (86.1%). The truth, then, bears no resemblance whatsoever to the narrative being spun by Sanders and his surrogates for, no matter how you slice or dice it, Bernie Sanders, is less popular and is receiving less support than he was four years ago in every state that has voted thus far.

And there are states Bernie won in 2016Oklahoma, Maine, and Minnesotathat shifted decisively away from him in 2020. In terms of states he lost in 2016, yes, he won Nevada and seems to have won California, but in both those casesas in every case so farhe still performed worse than in 2016, and, in the case of California, significantly worse. In fact, as I noted before, Nevada was also a bit of a red herring in that, since it was a caucus, it overrepresented his support with nonwhites, just as caucuses overrepresent Bernies support in all groups, but the media and, it seems, the Bernie campaign, took the bait and thought Bernie just might have chipped into African-American support enough to topple Biden. In the end, non-caucus South Carolina put that nonsense to rest six feet under and then some.

How can we expect a candidate to mobilize a solid coalition to defeat Trump in November if he cant even get that supposed coalition out to get him the nomination first? How can we expect a candidate who claims to be able to mobilize millions of people in the streets to bring pressure to bear on opponents once he is president if the very people he is talking about stay home when he is in the fight of his life to win the nomination? How can we expect him to win when hes losing support compared to what he had in 2016?

The answer is: we cant.

Polls have been wrong before (but not usually), so Bernie might have a miracle and stay alive in theory (that would be a miracle) or at least in a cosmetic sense. But there are many recent polls that have Bernie being crushed tonight in just about every state or losing narrowly in territory like Washington state that should be favorable to him. And while, yes, the pollsters missed big in Michigan in 2016, theyre at least good enough to be on the lookout to avoid similar mistakes based on the same errors. But the fact is that, just like in 2016, even if Bernie does win Michigan, he still wont turn it around. He will still lose big in other states and the delegate gap for him will only grow; it is just a matter of how quickly that gap will grow.

Once this becomes obvious after tonight, will Bernie lose and bow out gracefully, or will he lose and lead (or at least not try to stop) a Sandernista terrorist insurgency against Biden and the Democratic Party as they try to marshal their strength against Trump? The fate of the general election may hinge on the answer to this question, but if 2016 is any indication, that will be bad news for Democrats, the country, and the world and good news for Trump, Putin, and selfish, nihilist anarchists

Bernie Sanders has fought for justice as he saw it his whole adult life. He has dedicated himself to trying to make the world a better place and fighting for many of the voiceless. He deserves credit for inspiring so many from such an underdog position back in 2015 when he first announced his presidential candidacy. But how you behave in defeat is often a defining aspect of how history passes judgement on your actions and a real revealer of character. Sanders was rightly called out for the way he went about losing in 2016, for dragging his feet and keeping up intense attacks on Clinton and the Democratic Party when it was clear he was not to be the nominee, substantively damaging Clinton in ways that helped Trump win the election, something I warned about throughout the 2016 election. This is truly the moment of truth for Bernie Sanders in twilight of his career. Will he be associated with unproductive, scorched-earth tactics that tore the left apart at the moment when Trump threatened the survival of the American republic as we know it? Or will Bernie understand, and move hard to make his followers understand, that some things are bigger than your movement and your passion?

The formal war is ending, and tonight is almost certainly the last time Sanders can put up any serious resistance in a delegate-rich state. His Waterloo will be Michigan. The only real question is if Sanders surrenders gracefully like General Lee at Appomattox or pulls a Saddam Hussein and allows his forces to melt away in order to mount a vicious guerrilla campaign once the big formal battles are over.

In the interest of full disclosure, Brian interned for Joe Biden from September-December, 2006.He is currently in no way professionally affiliated with the Biden 2020 campaign, nor is receiving any compensation from it nor the Democratic Party nor any related super-PACs, campaigns, or other political groups involved in the 2020 nominating contests and elections.

See related articles: The Best Guide to Super Tuesday (no, seriously): Bidens Got This (and the Nomination), Democrats Look Disastrous, But Biden May Yet Save Them from Themselves Starting in South Carolina, Sandernista Political Terrorism II: Sanders Derangement Syndrome, the Liberal Tea Party, & How Nevada Riot Pretty Much Sums Up Team Bernie, and The Sandernista Political Revolution Handbook: A Matchup Game of Bernie Sanders Talking Points & Those of His Fans/Supporters

2020 Brian E. Frydenborg all rights reserved, permission required for republication, attributed quotations welcome

Brian E. Frydenborg is an American freelance writer, academic, and consultant from the New York City area.You can follow and contact him on Twitter:@bfry1981. He also just recently authoredA Song of Gas and Politics: How UkraineIs at the Centerof Trump-Russia.

If you appreciate Brians unique content,you can support him and his work bydonating hereand, of course, please share the hell out of this article!!

Feel free to share and repost this article onLinkedIn,Facebook, andTwitter. If you think your site or another would be a good place for this or would like to have Brian generate content for you, your site, or your organization, please do not hesitate to reach out to him!

Related

Read this article:

The Death Throes of the Failed Sandernista Revolution - Real Context News

Pulsometer watches – How fast is your heart beating? – Trends and style – WorldTempus

In 2020, when every smartwatch and fitness monitor can tell you your heart rate, why in the world would you buy a mechanical watch with a pulsometer? It cant show your current heart rate spontaneously, alert you if your heart rate becomes too high or too weak, or send you a notification in the event of arrhythmia. It cant save your life, like some smartwatches apparently have.

And yet, in 2020, watch brands continue to offer watches with pulsometers. Watchmaking history records that this complication dates back to the start of the 18th century, when two Englishmen came up with the idea. Doctor John Floyer and watchmaker Samuel Watson joined forces to create the Physicians Pulse Watch, an instrument that could calculate a patients heart rate by use of a graduated dial. By the mid-19th century, physicians had access to sphygmographs (or pulsographs) to record patients heart rates, but pulsometer watches continued to be very popular with doctors in the 18th and 19th centuries, because they were more practical and easier to use.

Watson's Pulse Watch

And thats their main advantage. At the time, they met a genuine need of the medical profession to be able to easily calculate a patients heart rate, by simply taking their pulse, and reading the result off the dial. These appropriately named doctors watches were as useful to the medical profession as pilots watches were to aviation pioneers in the era of astronomical navigation.

By pure coincidence, Graham and Montblanc unveiled their latest pulsometer watches the Graham Chronofighter Pulsometer Ltd. and the Montblanc Heritage Manufacture Pulsograph Limited Edition just a few weeks apart.

They are both chronographs, because thats the complication needed to calculate heart rate. They both feature a graduated scale from 40 to 200, located between the 2 and 9 oclock positions, which represents the number of heart beats per minute; and they also both work on the basis of 30 beats (60 beats for Watson's Pulse Watch)

Les deux modles Montblanc et Graham fonctionnent sur une base de calcul de 30 pulsations. Graham / Montblanc

In practical terms, to calculate heart rate, you take the pulse with your spare hand and engage the chronograph while counting 30 beats. After 30 beats, you stop the chronograph, and the hand indicates the number of beats per minute on the graduated scale.

This is how both watches work. Aesthetically, however, they are very different.

Chronofighter Vintage Pulsometer Ltd Graham

The Graham Pulsometer is a chunky 44 mm sports watch in steel with a sunray blue dial (previous versions came with silvered and black dials). But it doesnt look like a chronograph, because it doesnt have the two traditional subdials. The chronograph function is primarily devoted to the pulsometer, via its central second hand. Further evidence of the pre-eminence of the pulsometer on this original model is supplied by the fact that the hours are discreetly indicated by dots, and the small seconds counter is completely blank. Apart from the pulsometer markings, the only other figures visible on the dial are the date and limited edition numbers. As with all Chronofighters, the crown with its impressive protection lever and the chronograph pusher are located on the left. The Calibre G1718 can be seen through the sapphire caseback. It beats at 28,800 vph, providing a power reserve of 48 hours.

Heritage Manufacture Pulsograph Limited Edition Montblanc

The Montblanc Heritage Manufacture Pulsograph Limited Edition marries the deliciously old-fashioned pulsometer with an elegantly refined and unapologetically vintage design featuring an 18K rose gold case, tobacco-coloured dial and sfumato strap. Classic elegance is the order of the day, with the two traditional chronograph counters, dauphine hands, railroad minutes track, domed dial and grained chapter ring. Inside, classical styling gives way to heritage and the weight of history. The Calibre MB.13.21 is a descendant of the famous Minerva 13.20, the first hand-wound monopusher chronograph movement, which cemented the reputation of Minerva chronographs in the 1920s and 30s, and whose main features it reproduces. The Calibre 13.21 is a beautiful movement, whose finishes can be admired through the sapphire caseback.

So, why buy a pulsometer watch? Even if this function is rarely used (and, honestly, how many people regularly use their chronographs or tachymetric scales?) its a historic watch complication that deserves to be remembered. The display leads to some original dial layouts, and its old-fashioned vibe fits well with the vintage-inspired zeitgeist.

Visit link:

Pulsometer watches - How fast is your heart beating? - Trends and style - WorldTempus

Britain has its first punk-rock government – Spectator.co.uk

The most surprising thing about the letter from Guardian and Observer journalists moaning about Suzanne Moores supposed transphobia is that it contained 338 signatures. This must be the first time a newspaper has had more writers than readers. What an extraordinarily bloated institution how does it survive? Through those often advertised workshops where Owen Jones explains to people how to write a column? Most bizarre.

Surprise number two was that these hacks were prepared to get themselves worked up about a perfectly reasonable piece, for once, by Moore but found no problem what-soever with Steve Bells disgusting and frankly racist depiction of Priti Patel in a cartoon. Patel, Indian and Hindu by ancestry, was portrayed as a bull with horns and a ring through her nose. All this on International Womens Day, too. The left likes its minorities and chicks only when they toe the line and dont get uppity, as I have mentioned before. The left likes clients, not people.

If I had been drawing Ms Patel, it would have been with a safety pin through her nose and a spiky hairdo. With every day that passes it seems to me more and more that we are experiencing Britains first punk-rock administration, pogoing up and down on decrepit institutions and cheerfully gobbing in the direction of its enemies the swamp, the blob, the establishment. It is a fairly glorious thing to behold. One hopes it endures longer than the 18 months or so in which punk was in ascendancy (roughly autumn 1976 to the spring of 1978, since you asked).

The social impact of punk was far more lasting and important than the music, which, by the time the Sex Pistols had dissolved, had already become a jaded and boring caricature of itself. The mistake people make is in seeing punk as a left-wing movement, largely because the awful old hippies at the New Musical Express and Melody Maker tried very hard to insist that it was and stamped on anyone who stepped out of line. Plus a change etc.

In truth it was anything but left-wing. It was anti-establishment, for sure it loathed the torpor of the 1970s, the desiccated institutions and the dead hand of an overbearing state. It loathed the BBC. It despised the big record companies and wished them gone, not because they were agents of capitalism, but because they didnt do capitalism well: they lacked dynamism. It didnt have much time for the trade unions it was union workers, at their unions behest, who refused to press the Sex Pistols single God Save the Queen, and the BBC (and WH Smith, which then had a big record department) which refused to play it. Before they got hammered into supine wokeness, the Jam were pro-Tory royalists, while Sham 69 were singing about the evils of socialism in Red London.

It is true that punk was anti-racist and anti-sexist, considering gender and skin colour an utter irrelevance, as we all surely should. But it was nonetheless born in the lower middle-class suburbs of our major towns and cities, among the people who a year later would propel Margaret Thatcher (from the same background) into No. 10 a tranche of the electorate never renowned for its leftish sensibilities. In the USA, punk was far more explicitly right-of-centre and a riposte to gentle leftish hippiedom you may search long and hard, but I doubt youll find a much more right-wing popular band than The Ramones and sure enough, in 1979 Ronald Reagan ousted Jimmy Carter.

The only big exceptions to the rule in the UK were the very left-wing Clash, led by an ex-public schoolboy, Joe Strummer, and the even further left Tom Robinson Band, led by Tom another public schoolboy, this time from Cambridge. Good bands, but wholly out of step with the real zeitgeist of the time, because of where they were from. To get a truer picture of punk, look at John Lydon vehemently pro-Brexit or the two best writers to emerge from those city suburbs and who chronicled punk, Julie Burchill and Tony Parsons. Not quite bleeding-heart liberals, any of them.

Popular music does not change the world. Not even the most incendiary and exciting leftie stuff from the 1960s Fortunate Son by Creedence Clearwater Revival, Ohio by CSN&Y, Masters of War by Dylan could prevent the bombing of Cambodia by the USA. But it is useful in indicating a certain appetite for change within the population, a dissatisfaction. There are many similarities between the UK now and the UK in early 1979. Back then we had endured a paralysed minority government led by Jim Callaghan and ineffectually buttressed by David Steels Liberals, with all the chaos that brought: the almost perpetual union strife, the rubbish piling up on the streets. As for the past three years, we endured until December a paralysed and hopelessly divided Conservative administration, and the chaos that brought, as we tried to respect the public vote and wriggle free of the European Union.

The vote in December, then, just like the vote in May 1979, was emphatically not for continuity but for change: real, dynamic change. And that means a government prepared to battle with the institutions that will do their damnedest to arrest that change primarily the civil service, but also the BBC, the judiciary, the infrastructure this liberal elite has built around itself. Call it the pink wall, if you like. It needs demolishing with every bit as much vigour as did the red wall in the north of England on 12 December.

Thatcher never quite quietened either the civil service or the wet reactionaries in her party. She flailed occasionally at the BBC, but rarely to great effect. This government realises far better that it is these institutions which need changing before anything else can be done. All together then, to that fine tune by the Ramones: Boris is a punk rocker, Boris is a punk rocker!

This article is only available to subscribers

Subscribe now and get your first month free

Follow this link:

Britain has its first punk-rock government - Spectator.co.uk

How will the new James Bond movie ‘No Time to Die’ navigate the coronavirus and post-MeToo world? – Sydney Morning Herald

Normal text sizeLarger text sizeVery large text size

Were driving just after dusk along a wooded country road, rain pitter-pattering on the windscreen, the white beams of the headlights cutting through the shrouding mist to reveal pine trees and furrows of sticky mud lining the roadside. We come to a gentle stop at a small guardhouse beneath a commanding silver sign, the CCTV cameras above watching us. The security guy punches his keyboard, waves us through. Thats when I see her.

Rene.

Zellweger, that is. Her beautiful filled and filtered face is plastered over a towering billboard on the side of a massive white, windowless sound stage at Pinewood studios, west of London, where parts of Judy the Judy Garland biopic were filmed.

But Im not here for Rene. Or Judy. Im here for Bond. James Bond. Nearly all the Bond films were shot here at Pinewood, beginning with Dr. No in 1962. We pass one sprawling sound stage after another there are 18 on the lot including a stretch of cleared land set aside for a massive new stage, testament to the voracious appetite for film and TV content in this age of streaming and nesting.

Located within the green belt, a swath of rural land that rings London, Pinewood opened in 1936 on the grounds of a Victorian manor house, Heatherden Hall. Thousands of films have been shot here, from classics like Oliver Twist (1948) to recent blockbusters like Star Wars: The Rise of Skywalker (2019). It hosts the 007 sound stage, one of the largest film stages in the world.

This is the first act in a press junket extravaganza for the latest and 25th James Bond film, No Time to Die. Its late October 2019, over two months before China will alert the World Health Organisation to several cases of an unusual pneumonia in the city of Wuhan. At this point, No Time to Die is pitched for an international release in the first week of April 2020. Box-office takings across Asia will be a crucial determinant of its success and the future of the Bond franchise. Vast amounts of money are at stake. This is the most expensive Bond movie ever made, with a reported budget of $US250 million ($380 million), a crew of 650, and enough sponsored product placement (Omega, Aston Martin, Heineken, Jaguar Land Rover, Bollinger) to make a marketing executives eyes water.

Film junkets on this scale are a devils bargain for journalists leaving us feeling guilty of churlish ingratitude if we dont deliver a positive, gushy story after weve been flown to film sets across the world and put up at fancy hotels, and shamefaced for selling our souls if we do. Scouts honour, Ive been a 007 fan since I was a kid, so Im torn between the Wowww, I cant believe Im on a James Bond set!!! response, and the captive anxiety of Oh no, theyve changed my interview schedule again, Will they give me enough time with Daniel Craig/Rami Malek/Lashana Lynch? and Crikey, how do I make this story not sound like a free ad for the film?

Daniel Craig on James Bond's attitude towards women: "Hes a hero, but hes also deeply flawed. It is up to audiences to decide on Bond. Not for me. Credit:Nicola Dove

Either way, my circadian rhythms have been doing a river dance since I arrived in the UK the day before, after 27 hours in a tin can in the sky. Just after dusk, about a dozen of us, all long-lead print and online reporters from Europe, Japan, the US and UK, pile into two minivans for the 10-minute drive from our hotel to Pinewood. But not before were asked to sign two embargoes and cautioned interviews should be straightforward and film-focused and not involve any games or gimmicks. Its not as if we could go crazy with plot spoilers: even the actors dont know how No Time to Die ends, as three alternatives were reportedly shot.

I know this because, in the interests of hard-nosed investigative reporting, I spent a night in a semi-coma googling fun facts such as 007 author Ian Fleming choosing the name Bond because he considered it short and manly, and his fictional super spy attending Fettes College in Edinburgh, where Sean Connery was the schools milkman in the mid-1940s.

Ursula Andresss famous scene in 1962s Dr. No.Credit:Alamy

Upon arriving at Pinewood, were ushered into Workshop 10, where a German journalist ahead of me is gazing wide-eyed gasp! at Ursula Andresss white cotton bikini from Dr. No (often dubbed the most famous bikini of all time), which is suspended in a tall glass cabinet in a corner. (I later learn, to my disappointment, that its a replica.) That iconic cinema moment when Andresss character, Honey Ryder, emerges from the glistening Caribbean waters all coppery and dripping was reprised by Daniel Craig in his nutcracking baby-blue togs and tanned, jacked physique more than four decades later in Casino Royale.

Craig in Casino Royale (2006) mirrored Ursula Andress's scene but for a different audience.Credit:

My attention switches to four framed Bond movie posters all Craig vehicles lined up across the walls in order of release: Casino Royale (2006), Quantum of Solace (2008), Skyfall (2012) and Spectre (2015), most featuring the gun-barrel silhouette of 007, brimming with adrenalin and testosterone, with a glam, sexy woman draped at his side.

Its hard to pinpoint the exact moment when excessive, smug masculinity became unfashionable. Even Craig himself has labelled Bond a misogynist, and hates the term Bond girls, something Im keen to ask him about. The problem for the ageing Bond franchise has not been finding crazier stunts, cooler gadgets and more luscious locations. The problem has been Bond himself. 007 is the most famous ladies man in modern cinema, a love em and leave em serial shagger whose pick-up and post-coital lines in the first four decades of the series sound amusingly sexist to 21st-century ears. Take the opening scene from You Only Live Twice (1967), when Sean Connerys Bond is under the sheets with Ling, a pretty Chinese woman:

Bond: Why do Chinese girls taste different from all other girls?Ling: You think we better, huh?Bond: No, just different. Like Peking duck is different from Russian caviar. But I love them both.Ling: Darling, I give you very best duck.

Ah, what a cultural shift has occurred since Roald Dahl, the acclaimed childrens writer who wrote the screenplay for You Only Live Twice, penned those gems. Or has it? Thirty years later, in Tomorrow Never Dies (1997), audiences were treated to the following:

Bond: I always enjoyed learning a new tongue.Miss Moneypenny: You always were a cunning linguist, James.

A pre-#MeToo-era scene from 1967s You Only Live Twice.Credit:Getty Images

Over the past 20 years, the Bond women have been empowered, especially so since Craig became the man from MI6. But can Bond survive the post-Harvey Weinstein world too? No Time to Die has been made at a particularly woke moment. The last film, Spectre, was released in November 2015, two years to the month before #MeToo went viral. No Time to Die risks hitting a new raw spot when everyone is chattering about gender and power dynamics. How do you update 007s man-whore ways without stripping him of his macho mojo?

That question has long been uppermost in the mind of Bond producer Barbara Broccoli, who has just sailed into this office/press room with her producer half-brother Michael Wilson. Broccoli, 59, and Wilson, 78, are lauded as Bond royalty.

Two more nights of shooting, sighs the balding, bearded Wilson in his deep, southern Californian drawl, sitting behind a tabletop of flickering digital recorders and smartphones.

Were exhausted; its been seven months, chimes in Broccoli, who has long, straight, chestnut hair, chocolate-brown eyes and a winning smile.

The wrap in two days time will be bittersweet, she reflects, because Daniel is saying its his last.

But is it really? one journalist cuts in. We managed to talk him around for this one, but I dont think well get him to come back, Broccoli says resignedly.

This is it, adds Wilson quietly.

Craig, who famously griped while promoting Spectre that hed rather slash his wrists than play Bond again, was reportedly talked around when Broccoli and Wilson waved a $US25 million cheque in front of him, plus a percentage of profits.

When one reporter asks if this film has been their biggest headache to date, the duo burst into raucous laughter. (Shooting was plagued by a string of hold-ups, from a change of director over creative differences, to Craig requiring minor ankle surgery after an on-set accident, to the damaged exterior of the 007 sound stage after a controlled explosion went awry.)

Theyre all headaches, says Wilson, tossing his head back, not knowing that the mother of all headaches is still ahead of him.

Broccoli is the daughter of renowned film producer Albert Cubby Broccoli, who in 1961 teamed up with theatre and film producer Harry Saltzman to raise money to bring Ian Flemings character to the big screen. (Saltzman had already put in a bid to the bestselling author for the screen rights.) The two men formed Eon Productions (an acronym for everything or nothing) to produce the first Bond film, Dr. No on a budget of $US1 million, which reaped $US59.5 million and paved the way for the high-grossing blockbusters that followed. When Skyfall hit cinema screens worldwide on the franchises 50th anniversary in 2012, it hauled in $US1.1 billion at the box office, an all-time Bond record. (Its successor, Spectre, raked in a highly respectable $US881 million, but was less warmly received by critics and audiences, which puts greater pressure on No Time to Die to succeed.)

From the outset, this has been a family franchise. Albert Broccoli was married to actor Dana Wilson, who already had a teenage son, Michael, from a previous marriage. The half-siblings spent time on the 007 sets, although over different decades, both moving up the production ranks until Cubby Broccoli passed the keys of the Bond kingdom, and its parent company Eon, to his two offspring in 1995, a year before his death. Since then, Barbara and Michael have held an iron grip on the franchise overseeing every casting decision, signing off on every line of dialogue, presiding over every phase of marketing. (Michaels two sons also work for Eon.)

The title of the movie, announced last August after more than two years of being called Bond 25, has drawn a mixed response from fans, given the word die has popped up so often Live and Let Die (1973), Tomorrow Never Dies (1997), Die Another Day (2002). The title is always difficult, observes Broccoli. I came in one day and thought, Thats it. Then I realised [No Time to Die] was actually the name of a film my father shot in the 1950s. But that made it more special to me. My dads legacy is prominent, all through these films.

Against considerable hand-wringing among her professional peers who believed a blond, rough-edged 007 would be met with a cool response from audiences, Broccoli was determined to cast Daniel Craig after seeing him in the 2004 British indie crime film Layer Cake. It proved an inspired choice: Craigs performance in 2006s Casino Royale, the origin story of 007, succeeded in rebooting the franchise, which was at a creative stalemate following four financially successful but low-calorie Bond outings by Pierce Brosnan. Supported by a more nuanced script, Craig elevated the super spy from a cheesy caricature into something gritty and vulnerable, a man with demons and a capacity for true love. Even Bonds trademark quips got an update: in a casino scene when 007 is asked by a barman whether hed like his vodka martini shaken or stirred, he replies, Do I look like I give a damn?

Glancing at the four movie posters on the wall opposite, Broccoli gushes that Craigs upcoming turn as 007 is his best (this film has an epic emotional quality; its going to blow them away). Rumours are rife that Bond himself will be blown away that in one alternative ending, Bond is killed, which would throw open the door for a radical reboot of the franchise for the post-Craig films. Slumdog Millionaires Danny Boyle, the first director, was replaced after a script dispute by Cary Fukunaga of True Detective fame. But the very title of the film, No Time to Die, suggests Bonds survival.

Whatever his fate, Broccoli and Wilson enlisted Emmy award-winning actor and scriptwriter Phoebe Waller-Bridge, of Killing Eve and Fleabag fame, to sharpen up the dialogue in a script already penned by Bond veterans Neal Purvis and Robert Wade and polished by director Fukunaga. Phoebe has great humour and wit, is in touch with the zeitgeist and Daniel is a fan of hers, so it was a no-brainer, says Broccoli.

Zeitgeist-y or not, its clear the duo is first and foremost aiming to create a huge popcorn hit. Whatever happens in the world in the meantime is outside their control. Nobody wants to make the last Bond film, says Wilson reflectively, adding that theyve followed most of the tried-and-tested formulas, including a liberal dose of exotic locations. We started filming in Norway, then Jamaica, then up to Scotland, then locations in London, then Matera in Italy for three weeks, then back here. It adds up to the usual travel adventure.

Daniel Craig was offered $US25 million plus a percentage of profits to play Bond for the fifth time.Credit:Nicola Dove

Bullets are firing everywhere inside a hotel on a rain-washed, dimly lit Havana street. I have no idea whats going on because Im stuck behind a wire barrier with two other journalists and a publicist, checking out a man who looks eerily like Daniel Craig walk towards us with a pastry and a wide smile. Daniel? I squint, before realising it has to be his stand-in.

This is the dream machine in action in the middle of Pinewood studios. Mark Tildesley, a blue-eyed, bespectacled 56-year-old who is the films head production designer, has already explained how he and his team took a reconnaissance mission to Cuba to suss out how they might film there, but were stymied by pesky politics (they kept asking how we were going to portray the country) and logistics (we faced the prospect of shutting down streets and knocking down walls).

And so, after sketching and taking photos of Havanas finest neoclassical architecture, Tildesley built this whole street at Pinewood in just nine weeks, including the facades of bars, nightclubs and a barber shop. Weve created a set more Havana than anything in Cuba, the cheery, rugby-mad Brit explains, standing beside a diagram of the set.

Weve already been taken on a tour of the production workshops, including those of the prop makers who handcraft 007s guns, but who gives a damn about a rubber Beretta 418 when you get to see a silver birch Aston Martin DB5 replica, the classic Bond car that first appeared in Goldfinger, firing a blaze of fake bullets from pop-out machine guns behind the headlights? (I shamelessly accept an offer from a publicist to take a photo of me beside one of the DB5s used in the film, which I intend to shamelessly post on Instagram.)

In a large tent about 50 metres from the set, we watch Daniel Craig on a monitor, taking his mark on the set of a Havana hotel, looking upwards and firing his gun with both hands. Few men, let alone those over 50, look better in a four-figure Tom Ford suit; few actors do inscrutable swagger better. Between takes, 007 walks into our tent. But the 007 in question is Lashana Lynch, whose character, Nomi, is given Bonds secret agent number after he leaves MI6 (the films opening premise has the super spy coming out of retirement in Jamaica after five years to help his CIA officer friend track down a missing scientist). Lynch, a tallish, vibrant and down-to-earth 32-year-old of Jamaican/British origin, says she is excited to be a major character in the franchise: My character is a black woman in 2019 overcoming so much.

Director Cary Fukunaga (centre) with Craig (left) and Lashana Lynch (right), who plays secret agent Nomi, one of No Time to Dies incredibly strong female characters.Credit:Nicola Dove

Which raises the question, will Lynch be the next James Bond, or is hers a one-off role for this film alone? As Barbara Broccoli has repeatedly said that Bond can be of any colour, but he is male, its unlikely to be the former. In 2018, Broccoli told The Guardian: We dont have to turn male characters into women. Lets just create more female characters and make the story fit those female characters.

In any case, the films have come a long way since the days when the Bond girls had names like Pussy Galore (Goldfinger, 1964), Chew Mee (Man with the Golden Gun, 1974) and Holly Goodhead (Moonraker, 1979). Even in the Pierce Brosnan era the female characters tended to be underwritten stereotypes, with the exception of Judi Dench as M.

As most of the journalists Im accompanying are seasoned entertainment reporters whove interviewed many of the Bond stars before, notably Daniel Craig, I ask one whats he really like. The reporter leans inconspiratorially, outside the earshot of a nearby publicist. Grumpy. He can be quite short with you.

Grumpy? I say, a little too loudly. Whats he got to be a grumpy about?

Daniel Craig on location in the southern Italian city of Matera.Credit:Oliver Palombi / MEGA TheMegaAgency.com

It's early December 2019, only weeks before the announcement of the novel coronovirus outbreak, and the worldwide promotion of No Time to Die is in full throttle. Im in New York for the major one-on-one and group interviews with the cast. As the full twinkling panorama of Manhattan slides into view on this freezing snowy night, my cab driver declares, I must come this way six times a day, but I never get sick of seeing that skyline. Ah, the heady thrill of Noo Yawk, a storybook city thats officially the most popular set location in the film and TV world, but a city that amazingly or perhaps not has seen only one James Bond film, Live and Let Die, set here, back in 1973. (That also happens to be the first Bond film Daniel Craig saw as a little boy.)

I ask the driver, who must be in his early 50s, whether hes a Bond fan, but he mishears me.

Bong fan??

No, no, James Bond, you know, 007. One of the old films, Live and Let Die, was partly filmed here.

Live and what???

His ignorance surprises me: a survey undertaken in 2012 by polling company YouGov found 60 per cent of Americans describe themselves as Bond fans, among them former presidents Bill Clinton, Barack Obama and the late Ronald Reagan.

You have 20 minutes, a publicist tells us the following morning in the conference room of the mega-elegant Crosby Hotel in lower Manhattan. About a dozen of us have already been given a sneak preview of the trailer for No Time to Die; now were set to meet Daniel Craig and Barbara Broccoli in a round table interview. When the pair walk into the room, Im struck by Craigs assured, commanding presence. Dressed in dark blue trousers and a jacket over an open-necked shirt, hes craggier in the face and slighter than I imagined, but by no means short, at 178 centimetres tall, or 5 foot 10.

A reporter kicks off by asking the 52-year-old how hes feeling now hes wrapped up his last Bond film. Craig circles the question briefly, saying he feels sad its over but is immensely proud of the five films, which brought all the Bond tropes back in, but in an original way. He admits, I didnt want to do this movie, I didnt want to do any of them, but Im so glad I did now.

Whats been the hardest thing about playing Bond? Doing this, he says dryly, looking down the table at us.

I didnt want to do this movie, I didnt want to do any of them, but Im so glad I did now.

I seize the awkward pause and ask how he thinks Bond evolved during his 007 tenure, particularly in light of the social earthquake of the #MeToo movement. Are you talking to me? he jokes, turning to face me with more than a little ice. Of course, you, I smile sweetly.

This is a long conversation Ive had with Barbara, he replies. How do you deal with Bonds misogyny, or his problem with women? Hes got a fairly messed-up attitude towards women. I dont make apologies for that. What weve done is find these incredibly strong female characters who hes come up against. Hes a hero, but hes also deeply flawed. It is up to audiences to decide on Bond. Not for me

Broccoli cuts in: Bond has already had trouble forming attachments, and thats part of the character. Hes an orphan. He fell in love with Vesper Lynd [in Casino Royale] and she broke his heart. Craig warms to the theme. We could throw in all kinds of references to the world, and I think we all agree it dates a film.

Within seconds of the duo exiting the room, there is a little echo, beginning with one reporter piping up, Well he was in a good mood today, while another enthuses, So much more open and chatty, and someone else offers nice mood. Even one of the publicists in the lift remarks on how chatty and cheery Daniel is today. Oh, what a tedious grind it must be, having to do interview after interview with reporters asking so many of the same questions. Craig can now return to his $US6.6 million brownstone across town, his day of soulless press meets over.

Im escorted to the 11th floor, seated in a spare chair outside the lift doors, and asked to wait. I count 10 publicists milling about, some crouched on the floor in the corridor, heads in their phones, at least one standing sentry at each door to the suites. Behind each of these doors a major star from the film is ensconced, waiting for reporter after reporter to march in with their list of questions.

A publicist checks her running sheet, says, Youre up next and ushers me down the hallway. Another opens a door with a minor flourish while a third inside immediately clicks on her phones timer for my 10-minute slot. Im about to meet French actress La Seydoux, who plays Dr Madeleine Swann, Bonds love interest in No Time to Die.

La Seydoux as Dr Madeleine Swann, Bonds love interest.Credit:Nicola Dove

I. Cant. Help. Looking. Resplendent in a black pants suit with black high-heel boots and pearl earrings, Seydoux is breathtakingly beautiful. The odd puffs of smoke billowing behind her ears, which I quickly realise are from her discreet vaping, add another disarming touch (smoking-hot French actresses being apparently exempt from no-smoking rules in New Yorks finest hotels). As she describes her character, the 34-year-olds soft, lilting French accent lulls me into a kind of trance.

Shes not there to please Bonds sexuality shes a real character I wouldnt call her a Bond woman.

How much of herself does she bring to the character?

I feed my characters with my experience. I always feel I am many women Im sorry, I hear your phone.

Jolted out of my reverie, I grab my handset in a panic. Its switched to silent.

Our heads turn to the offending publicist. Shes been rustling her notes, for which she apologises profusely. Confused by how Seydoux has mistaken a clipboards paper-shuffling for a ringtone, I offer irrelevantly, Do you find interviews boring?

Nooo Its interesting to speak about what you do. I like it when its a conversation like this you exchange ideas You never know how people will pursue you purr sue? No, no per ceeeve you

She doesnt strike me as someone who worries about what others think of her, I suggest.

Our time up, I ask La Seydoux whether shed like to see a female Bond. I dont really care, she says.

No, not so much before adding that were all a mass of contradictions. I am a very scary person, which she immediately corrects to scared, adding, I am strong and I am weak. I like to be in the light, but I also hate it.

Our time up, I ask whether shed like to see a female Bond. I dont really care, she says, as Im walking out the door.

After another 10 minutes or so, Im escorted deeper down the celebrity corridor, where another door is flung open. Im about to enter the villains lair.

Rami Malek plays the films villain, Safin.Credit:Nicola Dove

The first thing you notice about Rami Malek is his distinctive honey-rich baritone voice. The second is that hes exceedingly polite and exudes a chill vibe. Sitting cross-legged, he patiently answers questions, and good-naturedly gets up to shake my hand at the beginning and end of the interview (the only star to do so during my time in Bonds world).

Im interested in how he manipulates his voice to suit his character, the villain Safin. I really dont enjoy the sound of my own voice, the 38-year-old admits. William Conacher [a British dialect coach] helped me get the phrase voice right for Freddie Mercury in Bohemian Rhapsody and gave me some ideas for the villain, which I took to Cary Fukunaga to see whether they would fit.

Did he research any of the early cat-stroking Bond villains? Not only did I go through the Bond villains, but a catalogue of cinema history and picked out all my favourite villains. His favourite? The former MI6 agent turned cyber terrorist, Raoul Silva, played by Javier Bardem in Skyfall, because of his backstory. Theres nothing simplistic about being a villain, observes Malek. What drives that human being to do what they are doing? Is their malice defined by them or defined by others?

We proceed to talk very briefly about his extraordinary journey being the son of Egyptian immigrant parents, having a twin brother, growing up in Los Angeles, going to school with fellow actor Kirsten Dunst and his astonishing rise. Look man, if you told me in the span of two years, Id be playing an icon like Freddie Mercury, then the villain in a Bond film, I would have laughed at you, he says. I dont take this for granted for a second.

After receiving his Best Actor Oscar statuette at the Academy Awards last year, he took a stumble on stage; there are videos of him on YouTube taking other falls. Is he a little clumsy? I dont think of myself as clumsy, he laughs. Perhaps I have a little too much on my mind.

Malek has an earnest reverence for his craft. When youre at this level and working with such talented people, there is not much room to be anything other than poised, specific and intense.

As Im leaving the hotel and grabbing my luggage for a mad dash to the airport, it occurs to me that Bond wouldnt be seen dead boarding a plane with a bag. I pass the highly engaging Lashana Lynch on her way to the lifts. You know, youre about the only reporter who still uses a notepad, she observes.

Well, I like to do some things the old-fashioned way, I reply, stealing a Bond line from Casino Royale. Lynch looks at me blankly, the reference clearly passing her by. I feel compelled to elaborate. I record, but the notes are for observational stuff. Ah, I see, she laughs. Hope youll still see the film.

It's early 2020. The much-awaited title song for No Time to Die by 18-year-old singer-songwriter Billie Eilish, beloved by Generation Z, has been released, and the publicity machine has the pedal to the metal in the final lap to the films opening. But news of the coronavirus has become increasingly alarming. While the entertainment industry is hardly a priority in the face of a global pandemic, those whose livelihoods depend on the production, distribution and promotion of films are hit hard as cinemas across China, South Korea, Japan and Italy close their doors in February.

On March 2, the founders of the worlds two biggest James Bond fan sites send an open letter to Eon, MGM and Universal calling for the postponement of the films release because of the public health risk. Then, on the rainy morning of Thursday March 5, my phone lights up with emails and texts. A statement has been issued from the offices of Michael Wilson and Barbara Broccoli: the release of No Time to Die will be postponed until November. The rescheduling is likely to cost unknown millions in cancellation fees and relaunches.

No Time to Die is the first Hollywood blockbuster to shift its release date because of the coronavirus. Suddenly, Lashana Lynchs words outside the lifts back in November seem oddly prescient.

Greg Callaghan flew to the UK and the US courtesy of Universal Pictures.

To read more from Good Weekend magazine, visit our page at The Sydney Morning Herald, The Age and Brisbane Times.

See the rest here:

How will the new James Bond movie 'No Time to Die' navigate the coronavirus and post-MeToo world? - Sydney Morning Herald

Global induced pluripotent stem cells market is expected to grow with a CAGR of 8.6% over the forecast period from 2019-2025 – GlobeNewswire

New York, March 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Induced Pluripotent Stem Cells Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" - https://www.reportlinker.com/p05874276/?utm_source=GNW 6% over the forecast period from 2019-2025. The study on induced pluripotent stem cells market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on induced pluripotent stem cells market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global induced pluripotent stem cells market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global induced pluripotent stem cells market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings1) Drivers Increased government fundings and rising industry focus on the development of novel therapies Rising interest in stem cell therapy2) Restraints High the cost associated with storage3) Opportunities Growing applications of iPS cells in several biopharmaceutical applications provides extensive potential to the key players in the market

Research Methodology

A) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industry

Our primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.

B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agencies

Segment CoveredThe global induced pluripotent stem cells market is segmented on the basis of derived cell type, application, and end user.

The Global Induced Pluripotent Stem Cells Market by Derived Cell Type Fibroblasts Amniotic Cells Hepatocytes Keratinocytes Others

The Global Induced Pluripotent Stem Cells Market by Application Drug Development Regenerative Medicine Toxicity Testing Academic Research

The Global Induced Pluripotent Stem Cells Market by End User Research Organizations Hospitals Biopharma Industries

Company Profiles Astellas Pharma Inc. Fate Therapeutics Inc. FUJIFILM Holdings Corporation Evotec SE Japan Tissue Engineering Co., Ltd ViaCyte, Inc. Vericel Corporation Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Acelity Holdings, Inc.

What does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the induced pluripotent stem cells market.2. Complete coverage of all the segments in the induced pluripotent stem cells market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global induced pluripotent stem cells market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.Read the full report: https://www.reportlinker.com/p05874276/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to read the rest:

Global induced pluripotent stem cells market is expected to grow with a CAGR of 8.6% over the forecast period from 2019-2025 - GlobeNewswire

HIV patient appears to be totally cured after stem cell treatment – BGR

A 40-year-old HIV patient has been declared cured after a promising treatment has left him with no active virus. The man, Adam Castillejo, was the subject of extensive research in early 2019 after doctors failed to find HIV in his body over an 18-month period after previously being diagnosed in 2003.

Castillejo, known by the nickname London Patient lived with the disease for many years, taking medicine to manage it since 2012. That same year he was diagnosed with Hodgkins Lymphoma, and later endured a bone marrow transplant. That operation may have ultimately cured him of HIV, and appears to have made him only the second person to ever be cured of the disease that causes AIDS.

As ScienceAlert reports, the bone marrow transplant that doctors performed on Castillejo used cells from a donor with a very special genetic quirk. The cells are thought to work against HIV in the body, but there was no guarantee that the transplant would provide any concrete benefits beyond treating the cancer.

However, it appears as though the decision to treat Castillejo with the unique stem cells worked in more ways than one, and last year doctors announced they couldnt find the virus in his body after 18 months. At the time, they were hesitant to declare the London Patient cured, but after a new round of testing returned the same results, they are more confident that the active form of the virus has indeed been defeated.

This is a unique position to be in, a unique and very humbling position, Castillejo told the New York Times. I want to be an ambassador of hope.

While this sounds like incredible news and for Castillejo, it certainly is the treatment is not an option for everyone. With cancer limiting their options, doctors used the stem cell transplant as a last resort to keep him alive. Its a serious operation and one that was only performed because Castillejos condition was so dire.

Castillejo and the other HIV patient who had similar results, known as the Berlin Patient, may be uniquely fortunate. The doctors note that there are others who have had the same transplant performed but did not improve as rapidly as the others. There are obviously many factors at work here, and as exciting as it is to see a second person cured of this terrible disease, theres a lot more work to be done before we can say HIV has been truly beaten.

Image Source: Pius Koller/imageBROKER/REX/Shutterstock

Mike Wehner has reported on technology and video games for the past decade, covering breaking news and trends in VR, wearables, smartphones, and future tech. Most recently, Mike served as Tech Editor at The Daily Dot, and has been featured in USA Today, Time.com, and countless other web and print outlets. His love ofreporting is second only to his gaming addiction.

Go here to read the rest:

HIV patient appears to be totally cured after stem cell treatment - BGR

Future Growth Of Animal Stem Cell Therapy Market By New Business Developments – News by aeresearch

Tea Sachets Industry Size 2019, Market Opportunities, Share Analysis up to 2025 By Market Study Report

New 2019 Report onTea Sachets Market size | Industry Segment by Applications (Functional Application and Leisure Application), by Type (Scented Tea, Leaf Tea and Other), Regional Outlook, Market Demand, Latest Trends, Tea Sachets Industr...

New 2019 Report onPhotomedicine Technology Market size | Industry Segment by Applications (Eye, Oncology, Otolaryngology, Department of Gynaecology and Other), by Type (Laser, Dichroic Light and Light-emitting Diode), Regional Outlook, M...

The immense research on the Narcotic Analgesics market summarized by topmost companies like : Sanofi S.A. Novartis AG GlaxoSmithKline PLC Pfizer Reckitt Benckiser Endo Pharmaceuticals having a huge growth rate worldwide.Growth Forecast Report on ...

New 2019 Report onProtein Kinase Inhibitor Market size | Industry Segment by Applications (Therapeutic, Diagnostic and Research), by Type (Serine/Threonine Protein Kinase Inhibitors and Tyrosine Protein Kinase Inhibitor), Regional Outloo...

Research Report onHospital-acquired Infection Diagnostics Market size | Industry Segment by Applications (Hospital, Clinics, Ambulatory Surgery Centers (ASC) and Others), by Type (Instrument and Reagents and Consumables), Regional Outloo...

Link:

Future Growth Of Animal Stem Cell Therapy Market By New Business Developments - News by aeresearch

‘London patient’ declared cured of HIV after three years – BioNews

16 March 2020

Three years after receiving a stem cell transplant, a man from London is the second patient in history to be cured of HIV, doctors report.

The study, published in The Lancet HIV, reports that the so-called 'London patient' has no detectable active HIV infection in blood, semen, or tissues 30 months after stopping anti-retroviral therapy. This follow-up comes a year after the first publication in Natureannouncing he was clear of the virus (seeBioNews 990).

'We've tested a sizeable set of sites that HIV likes to hide in and they are all pretty much negative for an active virus,' the study's lead author Dr Ravindra Gupta, from the University of Cambridge, told AFP. 'We propose that these results represent the second ever case of a patient to be cured of HIV.'

Adam Castillejo who recently decided to go public with his identity in the New York Times had been diagnosed with HIV in 2003 and then additionally with advanced Hodgkin's Lymphoma in 2012. After failed rounds of chemotherapy and attempts to transplant his own stem cells, he received a donor stem cell transplant in 2016 to treat his blood cancer. Similar to the 'Berlin patient' (the first person known to be cured of HIV) in 2011, the transplant came from a donor carrying a rare genetic mutation present in less than one percent of Europeans, which prevents HIV from entering the affected cells via the CCR5 receptor.

'This is a unique position to be in, a unique and very humbling position,' Castillejo told the New York Times. 'I want to be an ambassador of hope.'

Now, 30 months after cutting off retroviral therapy, the doctors reported no active infection in Castillejo's blood, cerebrospinal fluid, semen, intestinal tissue, or lymphoid tissue. Whatever traces of virus material could be found in the system are likely so-called fossil traces, which cannot replicate and harbour no risk of reoccurrence of the infection.

Dr Gupta said that this is to be expected. 'It's quite hard to imagine that all trace of a virus that infects billions of cells was eliminated from the body,' he explained.

Scientists agree that stem cell transplants will notbe a feasible treatment for the millions of people around the world infected with the virus. With a tenpercent mortality rate,bone marrow transplants are mainly used to treat cancer patients when no other options are available, and current antiviral drugs can enable HIV patients to live long and healthy lives. However, observing these 'cured' patients could provide helpful insights for the design of future genome editing tools to treat and cure HIV.

Professor Sharon Lewin from the University of Melbourne, Australia, said the case was exciting but warned: 'We need to also place it in context - curing people of HIV via a bone marrow transplant is just not a viable option on any kind of scale. We need to constantly reiterate the importance of, prevention, early testing and treatment adherence as the pillars of the current global response to HIV/AIDS.'

More:

'London patient' declared cured of HIV after three years - BioNews

Transcript: Disabled and out of money in North Korea – BBC News

This is a full transcript of Disabled and out of money in North Korea as first broadcast on 13 March and presented by Beth Rose

JITE- I got a few stares of course. I'm bald. I had a beard. I was in a wheelchair. I'm black. The first two that I went to said, "No, no, no, we probably can't do that." I didn't want to do something which was challenging for me only, rather than North Korea. Oh, well that's a tough place to go to.

[jingle: Ouch]

BETH-I've been so excited about bringing you this Ouch podcast. A few months ago I received an email. It said, "Hi Beth, a friend of mine, Jite Ugono has multiple sclerosis, or MS, and uses a wheelchair. He's just about to travel to North Korea. Would you like to talk to him?" "Yes," was my answer, "very much so."

I'm Beth Rose, and you're listening to the BBC Ouch podcast, and for a while Jite has been on my mind. From the day he flew to China to get his visa, to the five days he would spend in the country we know very little about. And finally, he's back. Also, just a quick note to say that this podcast was recorded long before the Corona virus outbreak.

[music]

BETH-Hello.

JITE-Hello, hi.

BETH-So how was the trip?

JITE-Everyone says surreal, but it was surreal. Being inside a communist country and being restricted. Also in a wheelchair, there are no provisions at all for wheelchair access and that kind of stuff. Most of the places I went to were only accessible by stairs, so they carried me, which was nice. And that's one of the good things about having a guide, because I had two guides and a driver.

BETH-So you said you were thinking about this trip a year ago. It's the kind of trip that most people won't even think you can do, so why did you suddenly decide to book your holiday to North Korea?

JITE-Well I've got MS so they said one of the treatments of MS could be stem cell therapy. So stem cell therapy involves chemo and the rest of it. I thought to myself why not do something as rare as stem cell therapy? It was almost like a redefinition of my identity. I didn't really want to be known solely because of MS or the treatment, because everyone's going to ask about the chemo. I wanted to do something else which was kind of equal and opposite.

BETH-It's quite rare, stem cell therapy for multiple sclerosis isn't it?

JITE-It is. I hadn't heard of it. Chemo for cancer, we know all about that, but as soon as she said chemo for this For me it was quite emotional because my mum died the year before of cancer and she went through chemo as well. It was a shock, but it was also some hope. It seems less bleak. What I have is Primary Progressive MS, a steady degradation of mobilities. And they have less treatment for that, so most other treatment comes for Secondary Remitting, when you have attacks and then you can recover.

BETH-So what does the chemo do?

JITE-Chemo reduces your immune system. So what they want to do is kind of knock out the immune system and then reintroduce the stem cells and then restart the immune system.

BETH-That sounds quite an intense treatment.

JITE-I was in hospital for a month. So I went in for chemo, I was in hospital for a week or so, first of all, came back out, did the injections, back into hospital for a month. It was tough going through, but easier when you do it in stages. You think, okay I'm going to do this chemo first, in ten days I'll do the injections. Bite size. So by the end of it it's like oh, I've done it. I think it taught me whatever I go through I have to be a bit more patient.

BETH-How long ago were you diagnosed with MS?

JITE-2009.

BETH-So you were quite young?

JITE-I'm 45 now, so yeah, the symptoms got worse maybe six or seven years ago in terms of difficulty walking. And that's the main thing. The first thing was the eyesight, so the eyes were playing up and I thought maybe I should go to the optician. It didn't really make a difference. So it got progressively worse. I did an MRI scan and then the consultant said, "Well, it could be MS." So I was kind of aware and I kind of knew that it was something quite serious. So when he came back and he said MS. You make a decision about how you're going to deal with it.

For me, it was you're not going to feel sorry for yourself because people go through worse. For me, it's only when I'm faced with stuff you realise you can do it. I didn't just want to survive. Because when you're diagnosed with stuff it's like getting through the day. Everyone says, "Oh, you're so brave. You went to work?" For me it's just one life, you can't spend it getting through the day, you want to do something else.

BETH-So was it when you were having your chemo when you were in hospital, the idea for North Korea?

JITE-It was actually the first consultation when she told me, "You're going to do stem cell therapy." They told me that I was going to be able to maybe walk with sticks and I thought, why waste it?

BETH-I feel like a lot of people would have had similar thoughts but maybe thought South of France would be quite nice?

JITE-It would have been challenging. If anyone said they were going to the South of France, oh okay. I didn't want to do something which was challenging for me only, rather than North Korea, oh well, that's a tough place to go to, regardless of whether you're in a wheelchair. It was important to me to do something which was challenging, not because of MS, not because of the wheelchair, but it was challenging.

BETH-So how do you go about booking a trip? Can you go to a travel agent?

JITE-I mean, that's what I did. So the first two that I went to said, "No, no, no. We can't do that, there's no access." And I was probably more determined. That's another lesson it taught me, it's more important for me that I wanted to do it. And no one was coming back to me to say, "Why don't you go?" So when the third person came back and said, "Actually, we could do that," the normal way of going to North Korea is through a group tour, with my condition anyway. You think about what the problems could be. Getting onto the coach. Holding people up.

So my tour was me on my own. I had two guides and a driver and that was it. They sorted out the visa to China and once you get to China you get the visa to North Korea from China.

BETH-Touching upon the issues of getting onto a bus, what is it like for you with MS? How does it manifest itself?

JITE-My balance is a problem. I can't really use my left leg at all. My eyesight's a problem. Maybe sometimes my memory and my vocabulary. They're difficulties which arose mainly because I did chemo. We know that the drugs are quite aggressive and concentrated, so they give you lots of water to dilute and because you're given that you're given drugs to help you relieve that stuff, so you're peeing like every ten minutes.

So it went down to probably once every hour and that became a problem and that affects your confidence, you're afraid to kind of go out, maybe there won't be toilets around, that's kind of what I was thinking about, going to North Korea.

BETH-Did you even know about that? Is there information about toilets or accessibility?

JITE-Not at all, not at all. It's only when I got there that I realised that the And sorry to go on about toilets, but it was important to me. [laughs] Okay, so in North Korea they had two types of toilets, they had the European toilets and then they had the Korean toilets, ground toilets, so you have to kind of balance, which I didn't even attempt. So everywhere we went to it was okay, "Is it a Korean toilet here or a European toilet?" Even the guides started to realise and started to know after a while.

BETH-I mean, that's such a gamble isn't it, not knowing the accessibility, not knowing what the toilet situation's going to be like. I'm guessing this was all in your mind?

JITE-Every problem has to have a solution. So before I went I'd got it up to you can pass an hour now, because I'd gone to the gym, I'd started doing core stuff, even in the plane, because it was ten and a half hours there. You think about the problems that you could face, it's personal of course, but also there are people around that can give you a hand.

And that was another thing, getting vaccinations was a problem, because when you do chemo and your immune system is low they don't advise that you have vaccinations. So I was intending to go to Korea in September but that was super close to my stem cell.

BETH-When you were flying, initially to China, what was going through our mind?

JITE-It was just getting through that first bit, hoping that someone's going to be there to meet me. The luggage I even took I had to make sure that I could carry. That's one of the solutions with a wheelchair, you're going to have to push the luggage as well so it can't be too big. Two pieces of hand luggage is what I took. That's what I was thinking about, I wasn't thinking about Pyongyang yet, I was thinking about how to get to China.

Beijing was packed, traffic everywhere. It was surprisingly western. The cars were German cars. In North Korea I had the guides, in China I didn't have guides, I had a person to take me from the airport to the hotel and that was it. So I didn't really have the confidence to kind of venture out. I got in a day before, so as soon as I landed in China I had to go and get the visa. As soon as you get the visa is when they give you a briefing, what you should and shouldn't do. The chap apparently had been doing it for 28 years, and no one had ever missed a briefing until me.

BETH-Ah! [laughs]

JITE-I mean, only because the person who picked me up said, "Oh, I can get the visa for you."

BETH-So they were being helpful, but actually

JITE-Yeah, so they went out and got the And I was appreciative, because getting in and out of the car was such a pain. And I am quite lazy naturally. If I can do without it then I won't do it, you know. So when they gave me an opportunity not to, oh okay. The travel agent contact in China was almost panicky on the phone, "No one's ever done this."

BETH-Wow, and I bet your heart was racing at that point.

JITE-To an extent, but I kind of knew what not to do. I mean, I'm not rude, and plus I'd seen stuff on YouTube and the guides tell you as well. So I was quite prepared. I flew into Pyongyang. The airport was a surprise. They only have a few planes that land for the day. They had one from Beijing, one from Shanghai and one from Moscow. There are soldiers everywhere, but the soldiers were, "Oh, look at this guy," I suppose maybe because I was a novelty in a sense. They'd never really seen someone in a wheelchair before. They were super helpful.

I'd met the guides at the airport as well. I got a few stares of course. I'm bald, and they have like five haircuts. I had a beard, I was in a wheelchair. I'm black. So all those things together.

BETH-So did you feel like you stuck out?

JITE-I didn't feel like I could relax, only because you feel like you're always on. I couldn't be anonymous, there's always someone watching, and that's tiring.

BETH-And did you feel like you were being watched by your guides?

JITE-Maybe the brief was to watch, but it is different when you have a relationship with people. So I didn't feel that way. I suppose they were constantly on about how great the leader is and after a while it got a bit tedious. Everyone walked around with badges. And it's difficult to tell because they spoke the language quite a bit. I don't know what they're saying.

BETH-They greeted you at the airport.

JITE-Yes.

BETH-Had they had disabled travellers before?

JITE-I don't think they had. What happens is that when you go on your own there is no camaraderie, I was mostly alone, but the advantage is you could probably get closer to people. There's good and there's bad about it.

BETH-What's it like, Pyongyang?

JITE-For me it was super quiet. I mean here we have adverts and stuff, people are selling you stuff all the time, there is different, you have pictures of the leaders surrounded by flowers and you have to respect that. If there's an image of a leader you can't really take a photo of it and you can't stand in front of it obscuring it. Or you can't crop it. Apparently they check people's phones to see what they've taken.

BETH-Did you take photos?

JITE-I took photos but they didn't check. But everywhere was empty. The place is set up for tourists but there are not many tourists. You go into a restaurant and there are people standing around. The restaurants are empty. It's bizarre.

BETH-So it's not really like a bustling city?

JITE-Not at all. Actually I went during King Il Sung who's the grandad of this present leader, it was his birthday, so there were two days of celebrations. I think there were more people on the street than normal, and then they had volunteers picking up stuff or gardening or I mean, because it's a communist environment they pay for everything but you have to work. They've got big roads, no cars.

BETH-Wow.

JITE-Yeah. The days were quite long. Maybe eight o'clock they'll come for me and then eight o'clock in the evening I'd finish. So there was always something to do and you were always with people. I think they had five channels, that was about it.

BETH-TV channels?

JITE-Five TV channels. On the channels they have the leader, Kim, pointing at stuff. He designed the theme park.

BETH-What's the tourist trail like?

JITE-There is an itinerary, so you would go to the war museum, flower exhibition. I went to their subway, it's the deepest subway in the world. So everything's the best in the world or the tallest in the world.

BETH-How did the subway compare to the tube?

JITE-It was more opulent. I only saw two of them and I think those are the two they show people, so maybe the others are less. There are chandeliers and stuff.

BETH-And the restaurants, you said you went into one, but they've got all the staff just waiting around?

JITE-Yeah, the restaurants seem to be for tourists, and because I was on my own, seven, ten people just standing around looking. I went to a casino, which was strange.

BETH-Oh, okay?

JITE-Yeah. But the casino was in the hotel. I think I was the only one in there. So when I went to North Korea I didn't take enough cash, and that was a problem obviously because no cards. So the guys were like, "You need some money? Go to the casino, you can change your money."

BETH-Oh, I thought you were going to say to like gamble and win.

JITE-At first I went to change money, but they didn't take sterling, they took US dollars and euros, but I didn't have either, so they allowed me to gamble, so I did.

BETH-Did you win? Did you get some money?

JITE-Yeah, I did. I don't want to get used to it. [laughs]

BETH-What game did you play?

JITE-Black Jack. I didn't know what was going on, but people around, they were almost cheering, and I was thinking by the time I won a hundred dollars I thought it's time to go, it's time to go. And everyone's around you willing you on and you don't want to disappoint them but you think okay, I'm going guys.

BETH-Is it expensive then, if you ran out of money and you're having to gamble to boost your-?

JITE-To boost. Okay, so I mean they have their own currency and they don't let you take the currency out.

BETH-I bet your guides quite enjoyed being in the casino.

JITE-The guides said, "Oh, we're not allowed in." Even when they came up to my hotel room I had to have Al Jazeera because that's the only English speaking channel, but they were almost transfixed. They were shaking their heads. Look around the world, look how happy we are type of thing. So you kind of understand why they would let Al Jazeera in, because Al Jazeera can be quite, look what's happening around the world, the protests here, the protests there.

BETH-And did you find people were willing to help you?

JITE-I think it was more because they see you as being vulnerable. "Oh, you're not comfortable, let me move your legs." So you always get somebody helping, which is not necessarily what you want all the time. Because you want to be able to be self-sufficient. Certainly in London people are a bit more patient to offer, "Okay, how can I help?" and then they stand back. In Korea it was, "Oh, we can do that for you." [laughs]

BETH-Did you see any other disabled people out and about?

JITE-No, I didn't.

BETH-No one at all?

JITE-I didn't at all. One of the guides was quite insistent on how great their society is. That's why they stay kind of thing, away from everyone else, and they obviously saw it as a good thing.

BETH-Oh, that's interesting. I was going some research, and there's a lot of reports from the UN and different charities where they say basically they send people away in an out of town community.

JITE-Yeah, they don't expect you to try. So maybe that was part of it, they were almost surprised that this person is doing something on their own.

BETH-And were they quite surprised how you just got on with everything?

JITE-Yeah, I suppose. Maybe they were. So even when I'd be going down the road people would lean over and look. They weren't rude about it. They would look, they were curious, but they weren't intrusive. And sometimes you look and they look away, except the kids, so the kids would be staring. But that's normal though, even in London you'll get kids staring. One of the guides took a video of me being lifted up the stairs, and it was quite tough to watch because you don't really see yourself as being vulnerable, except when you see it.

It's like hearing a recording of yourself and you think oh, do I sound like that? Or do I look like that? Am I really that vulnerable kind of thing? No wonder everyone helps. [laughs] It was tough to see. I didn't really see the footage until I got to the hotel and you kind of think, you know, is that how it is? They were helpful, and it sounds ungrateful almost, but it is what you think about.

It's a lack of confidence to think people only help you because you look so vulnerable. Maybe people are just nice. And that was one of the good things about going to North Korea. People say that Londoners are quite cold and I don't find that, Londoners can be helpful, and especially if you're patient enough. And MS for me does that, it allows you to be patient.

BETH-So what kinds of things is nice to have help for?

JITE-Probably getting in and out of cars. In London not so much, in London you kind of want to get strong. I know that I'm going to have to get in a car, and not everybody gives the same level of help, so you have to be self-sufficient. In North Korea there's no need. And I'm never going to be in North Korea again.

BETH-How did the access pan out? Because that was the big mystery wasn't it really? I mean, you had no idea.

JITE-It was just people lifting me. Only one place, the museum was difficult.

Follow this link:

Transcript: Disabled and out of money in North Korea - BBC News

Tired of The Coronavirus? Here Are 10 Good News Stories You Need Right Now – ScienceAlert

Life during a global pandemic takes on a surreal quality. The ubiquitous presence of social media and a constant fire hose of coronavirus news can make it particularly hard if you're already feeling anxious.

So, we've put together a little round-up of recent science news that we find inspiring, encouraging, and worthy of note in these trying times.

In a world first, surgeons at Oregon Health & Science Institute have used the CRISPR gene-editing technique to attempt a cure for Leber congenital amaurosis, a rare genetic condition that causes blindness in early childhood.

While we await results on how this experiment worked out, this achievement joins a list of other medical uses of the technique, including the search for a Huntington's disease cure, herpes, HIV, and immunotherapy for some types of cancer.

Living at a time when medical researchers have this powerful tool at their disposal is certainly a good news item in our books.

In February, a huge stock of 60,000 seed samples was added to the Svalbard Global Seed Vault nestled inside a mountain in Norway's Svalbard archipelago, including the first-ever heirloom seed deposit by an indigenous US tribe.

Increasing deposits to this safehouse of crops reflect growing worldwide concern about potential loss of biodiversity and food security - but these actions also demonstrate a beautiful commitment to our future generations.

The virus strains that cause influenza are shapeshifters, constantly moving beyond our ability to immunise against them - hence, we need annual flu shots to stay ahead of the disease. A 'universal' flu vaccine would give us a huge advantage in this race, and there's now a truly promising candidate on the cards.

The vaccine, called FLU-v, has successfully passed phase I and phase II clinical trials, demonstrating its safety in human subjects; it's been found to induce immune responses that last at least six months. We can't wait to see the results of the next phase of trials.

A new type of contact lens could restore the colour spectrum limitations in people whose eyes struggle to tell apart green and red hues.

This brilliant technology already exists in some cleverly designed sunglasses; soon, people might also have access to it in the highly convenient form of contacts, thanks to a team of engineers at Tel Aviv University.

'Normal' image of a tree; colour blind version; corrected version. (Sharon Karepov/Tel Aviv University)

Researchers have announced that for the second time ever, a patient carrying the HIV virus has been declared cured, with no trace of infection in his blood 30 months after he stopped traditional treatment, undergoing a specialised type of stem cell therapy.

The achievement doesn't constitute a generalised cure, because the patient also had a type of lymphoma that enabled him to receive this experimental treatment; but it demonstrates a real breakthrough in medical science, showing scientists are able to push the boundaries like never before.

The tiny South Pacific nation of Niue recently accepted a unique honour, as it became the first country to be formally accredited as an International Dark Sky Place.

This accreditation is bestowed by the International Dark-Sky Association (IDA), a conservation non-profit charged with preserving the naturally dark night-time environment, defending it from the intrusive disturbances of artificial light pollution.

There's no end of scientific research charting the negative effects of light pollution, whether on animals, plants, or human health; this honour emphasises that seeking a truly dark night sky remains as important as ever.

Hydrogen fuel is one of the more promising zero-emissions options around - if only we could produce it cheaply and without needing insane amounts of energy input.

Now, a team of researchers in Tokyo have managed to do just that, refining a method that produces hydrogen fuel using just a few basic ingredients, including light and a particular type of rust. A new study shows this method yields 25 times more hydrogen than existing methods.

Speaking of sustainability, one of the biggest challenges to widespread adoption of renewables remains the problem of large-scale storage. However, there is one excellent solution to this problem - pumped thermal electricity storage. This approach stores electricity by turning it into heat, then turning it back into electricity when needed using an engine.

Unlike pumped hydro, which requires specific geographic requirements, this type of storage can be built in many places, and it uses thermodynamic principles to store electricity in the form of heat. And the best part? It's already being tested in pilot plants.

In June 2019, an odd paper made waves after it was published in Scientific Reports. The scientific community was quick to voice their concerns over this flawed study, which claimed that the Sun's movements were the real cause of anthropogenic global warming.

Now, the editors of the well-known journal have corrected the scientific record, issuing a retraction notice that explains the errors,showing that even if something incorrect initially slips through peer review, the scientific process is still rigorous enough to fix the mistake.You can read about this fascinating case in full here.

A new report by the non-profit Project Drawdown has outlined a whopping 76 solutions the world already has at hand if we want to slow down climate change. These strategies - from shifting our means of energy production, to reducing food waste and empowering women - span across all sectors.

Furthermore, these solutions are actually cheaper than maintaining the status quo (also known as 'doing nothing'). Project Drawdown estimates that if we implemented these 76 solutions, it would result in savings of up to around US$144 trillion of avoided climate damage and pollution-related healthcare costs. Tell everyone - we can do this.

More here:

Tired of The Coronavirus? Here Are 10 Good News Stories You Need Right Now - ScienceAlert

Eye health: Testing the safety of stem cell therapy for age-related macular degeneration – Open Access Government

In 2020, the National Eye Institute is launching a clinical trial to test the safety of a patient-specific stem cell therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). The protocol is the first of its kind in the United States to replace a patients eye tissue with tissue derived from induced pluripotent stem (iPS) cells engineered from a patients own blood.

If successful, this new approach to AMD treatment could prevent millions of Americans from going blind. AMD is a leading cause of vision loss in people age 65 and older. By 2050, the estimated number of people with AMD is expected to more than double from 2.07 million to 5.44 million.

The first symptoms of age-related macular degeneration are dark spots in ones central vision, which is used for daily activities such as reading, seeing faces and driving. But as the disease progresses, the spots grow larger and increase in number, which can lead to significant loss of the central vision.

There are two kinds of AMD: the neovascular, or wet, form and the geographic atrophy, or dry form. Remarkable progress has been made in the ability to prevent vision loss from the neovascular form. In particular, anti-VEGF therapy has been shown to preserve vision required for driving among about half of patients who take it for five years.

By contrast, no therapies exist for treating geographic atrophy. Should this NEI-led study, and future studies, confirm the safety and efficacy of iPS cell-derived RPE-replacement therapy, it would likely be the first therapy approved for the treatment of geographic atrophy.

To produce the therapy, we isolate cells from a patients blood and, in a lab, convert them into iPS cells. These iPS cells are theoretically capable of becoming any cell type of the body.

The iPS cells are then programmed to become retinal pigment epithelium (RPE). RPE cells are crucial for eye health because they nourish and support photoreceptors, the light-sensing cells in the retina. In geographic atrophy, RPE cells die, leading to the death of photoreceptors and blindness. The goal of the iPS cell-based therapy is to protect the health of the remaining photoreceptors by replacing dying RPE tissue with healthy iPS cell-derived RPE tissue.

We grow a single-cell layer of iPS cell-derived RPE on a biodegradable scaffold. That patch is then surgically placed next to the photoreceptors where, as we have seen in animal models, it integrates with cells of the retina and protects the photoreceptors from dying.

This years clinical trial is a phase I/IIa study, which means it will focus solely on assessing the safety and feasibility of this RPE replacement therapy. The dozen participants will have one eye treated. Importantly, everyone will already have substantial vision loss from very advanced disease, such that the therapy is not expected to be capable of significant vision restoration. Once safety is established, later study phases will involve individuals with earlier stage disease, for which we are hopeful that therapy will restore vision.

A safety concern with any stem cell-based therapy is its oncogenic potential: the ability for cells to multiply uncontrollably and form tumours. On this point, animal model studies are reassuring. When we genetically analysed the iPSC-derived RPE cells, we found no mutations linked to potential tumour growth.

Likewise, the risk of implant rejection is minimised by the fact that the therapy is derived from patient blood.

Several noteworthy innovations have occurred along the way to launching the trial. Artificial intelligence has been applied to ensure that iPS cell-derived RPE cells function similar to native RPE cells. In addition, Good Manufacturing Practices, have been developed to ensure quality control, which will be crucial for scaling up production of the therapy should it receive approval from the U.S. Food and Drug Administration. Furthermore, the iPS cell-derived RPE patch is being leveraged to develop more complex RPE/photoreceptor replacement therapies.

Potential breakthroughs in treatment cannot move forward without the support of patients willing to participate in clinical trial research. Patients who volunteer for trials such as this are the real heroes of this work because theyre doing it for altruistic reasons. The patients in this first trial are not likely to benefit, so they are doing it to help move the field forward for future patients.

Editor's Recommended Articles

Read this article:

Eye health: Testing the safety of stem cell therapy for age-related macular degeneration - Open Access Government

Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing…

In this report, the global Cancer Stem Cell Therapy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Cancer Stem Cell Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Cancer Stem Cell Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2542097&source=atm

The major players profiled in this Cancer Stem Cell Therapy market report include:

The following manufacturers are covered:AVIVA BioSciencesAdnaGenAdvanced Cell DiagnosticsSilicon Biosystems

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAutologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOther

Segment by ApplicationHospitalClinicMedical Research InstitutionOther

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2542097&licType=S&source=atm

The study objectives of Cancer Stem Cell Therapy Market Report are:

To analyze and research the Cancer Stem Cell Therapy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Cancer Stem Cell Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Cancer Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2542097&source=atm

See more here:

Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing...

Single Cell Analysis Market Size Worth $8.02 Billion By 2027 | CAGR: 16.9%: Grand View Research, Inc. – Yahoo Finance

SAN FRANCISCO, March 16, 2020 /PRNewswire/ -- The global single cell analysis marketsize is expected to reach USD 8.02 billion by 2027, registering a CAGR of 16.9% during the forecast period, according to a new report by Grand View Research, Inc. Advancements in molecular techniques which resulted in higher accuracy, ability to perform multiple omics analyses in one cell, and automation, has lowered the barriers for implementation of single-cell analysis techniques across various end-use settings. As a result, companies are investing in introducing novel solutions to accelerate the identification and quantification of genetic information in individual cells for research programs, thereby contributing to revenue growth in this market.

Grand_View_Research_Logo

Key suggestions from the report:

Read 150 page research report with ToC on "Single Cell Analysis Market Size, Share & Trends Analysis Report By Product, By Application (IVF, Cancer, Immunology, Neurology, Stem Cell, Non-invasive Prenatal Diagnosis), By End Use, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/single-cell-analysis-market

This technology has addressed several research challenges with respect to biological intricacies in stem cell biology, tumor biology, immunology, and other therapeutic areas. This leads to improved therapeutic decision-making with regards to precision medicine, thereby driving the adoption of these assays in personalized therapeutic development.

The growth in research publications depicts the increasing R&D investments. Since R&D activities are considered as the foundation of innovation, investments in R&D activities signify a healthy growth prospect for the single cell analysis market. Moreover, the establishment of new single cell genomics centers in the past years is anticipated to boost the uptake of instruments and consumables for single cell analysis, thus driving the growth.

Grand View Research has segmented the global single cell analysis market on the basis of product, application, end use, and region:

Find more research reports on Biotechnology Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: sales@grandviewresearch.comWeb: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

View original content:http://www.prnewswire.com/news-releases/single-cell-analysis-market-size-worth-8-02-billion-by-2027--cagr-16-9-grand-view-research-inc-301024572.html

SOURCE Grand View Research, Inc.

Go here to read the rest:

Single Cell Analysis Market Size Worth $8.02 Billion By 2027 | CAGR: 16.9%: Grand View Research, Inc. - Yahoo Finance

Autologous Stem Cell Based Therapies Market 2020: Potential Growth, Challenges, Attractive Valuation | Key Players: Anterogen, Holostem Advanced…

Global Autologous Stem Cell Based Therapies Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Autologous Stem Cell Based Therapies industry, focusing on the main regions and the main countries (United States, Europe, Japan and China).

Market Segmentations: Global Autologous Stem Cell Based Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

Based on type, report split into Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells.

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases.

The report introduces Autologous Stem Cell Based Therapies basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Autologous Stem Cell Based Therapies Market for the coming few years have also been included in the report.

Autologous Stem Cell Based Therapies Market landscape and market scenario includes:

The Autologous Stem Cell Based Therapies industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/4403641/autologous-stem-cell-based-therapies-industry-mark

CHAPTERS COVERED IN THIS REPORT ARE AS FOLLOW:

Get Special Discount Up To 50%, https://inforgrowth.com/discount/4403641/autologous-stem-cell-based-therapies-industry-mark

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

See original here:

Autologous Stem Cell Based Therapies Market 2020: Potential Growth, Challenges, Attractive Valuation | Key Players: Anterogen, Holostem Advanced...